Physician profile
David B Thomas
NPI 1104860329
$1,937.56
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $366 · 2021: $110 · 2023: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.53 | 2019-2023 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $517.64 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.48 | 2019-2020 | |
| Janssen Biotech, INC. | $110.51 | 2019 | |
| Gilead Sciences, INC. | $85.36 | 2019 | |
| Shire North American Group INC | $82.84 | 2019 | |
| Braintree Laboratories, INC. | $73.31 | 2021 | |
| Romark Laboratories, Lc | $65.44 | 2019-2020 | |
| Redhill Biopharma INC. | $55.41 | 2020 | |
| Concordia Pharmaceuticals INC. | $43.75 | 2019 | |
| Daiichi Sankyo INC. | $27.19 | 2019 | |
| Covidien Lp | $17.31 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.21 | 2019 | |
| Boston Scientific Corporation | $13.28 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.77 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.74 | 2019 | |
| Merck Sharp & Dohme LLC | $12.00 | 2019 | |
| Ucb, INC. | $11.76 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $8.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.